

## TETRATHERIX EXECUTES GLOBAL DISTRIBUTION & SUPPLY AGREEMENT WITH HENRY SCHEIN CONFIRMING ITS COMMERCIALISATION READINESS

### HIGHLIGHTS:

- Finalisation of terms provides a clear path for Tetratherix (TTX) to commercialise its first product for bone regeneration applications with a global leader & distributor of health care solutions
- Establishes imminent transition to commercialisation of TTX's first product in 2026
- Construction begins of TTX's expanded, advanced manufacturing facility to meet anticipated global demand.

**Tetratherix Limited (ASX: TTX) (Tetratherix)**, a developer of novel clinical products based on its patented biomaterial polymer platform technology, is pleased to announce the execution of a global exclusive distribution and supply agreement with **Henry Schein, Inc. (Nasdaq: HSIC)**, the world's largest provider of health care solutions to office-based dental and medical practitioners. Execution of this commercial contract provides a clear and executable pathway for the first Tetratherix product launch in the US and other major markets.

The **global exclusive distribution agreement** is the next step in the partnership detailed in the Tetratherix IPO prospectus (see ASX announcement 27 June 2025) (Prospectus) for Tegenix - the Company's universal bone regeneration technology.

The agreement confirms **Henry Schein** as the Tetratherix distribution partner for **Tegenix**, the Company's initial product for dental surgery. The agreement provides for initial and renewal terms, which are subject to agreed minimum purchases, and facilitates immediate access to **Tegenix** for Henry Schein's established global sales and distribution network.

**Will Knox, CEO of Tetratherix**, said:

"Finalisation of these terms validates Tetratherix's initial commercial rollout and confirms a scalable route to market for Tegenix with a global leader in this space. Consistent with the communicated strategy in our IPO Prospectus, we anticipate the first commercial shipment to HS to occur in FY27 following FDA 510(k) clearance of Tegenix."

Tetratherix will strategically and deliberately launch its first commercial products based on a market seeding program, ensuring controlled early adoption, clinician engagement and robust post-market feedback.

SEE OVER

## Manufacturing Facility Construction Commenced

To meet this and anticipated future global demand, Tetratherix has commenced construction of its additional advanced manufacturing facility at its Alexandria campus in NSW.

The facility is designed to further support the expanded production of Tetratherix's synthetic polymer platform products to meet anticipated global demand. The construction of the facility will meet regulatory and quality requirements and is expected to be validated and operational in CY26. The facility has been designed with scalability in mind, supporting both near-term dental applications and future expansion into additional clinical indications.



## About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) (HS) is a solutions company for health care professionals powered by a network of people and technology. A FORTUNE 500 Company and a member of the S&P 500® index, HS is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The HS network of trusted advisors provides more than 1 million customers globally with solutions helping office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively.

**< ENDS >**

Authorised for ASX release by the Board of Tetratherix.

For further information, please contact:

Jacob Pfeffer  
General Counsel | Company Secretary  
+61 425 194 200  
[jacob.pfeffer@tetratherix.com](mailto:jacob.pfeffer@tetratherix.com)  
<https://tetratherix.com/>